EGFR and non-small cell lung carcinoma: An enrichment of co-alterations in several genes potentially activating the Wnt/β-catenin pathway, hormonal signaling, and cell cycle was observed in the EGFRM+ cases as compared to those with EGFR-wt, suggesting the pathogenetic role of these genetic co-aberrations in advanced EGFRM+ NSCLC [12].